Posts by ichor_developer

News Release NEW YORK, NY: The second annual Life Extension Advocacy Foundation (LEAF) Ending Age Related Diseases Conference was held in New York City July 11-12th. This conference brought together many of the top minds in the biotechnology rejuvenation field, including Dr. Kelsey Moody, CEO at Ichor Therapeutics, Inc. Dr. Moody also held a workshop prior to the conference, on July 10th. The workshop was held in the Cooper Union Square as two 1.5-hour sessions. Here, he discussed some of the main elements to developing and maintaining a successful biotechnology company, specifically in the aging field. Dr. Moody has grown Ichor from a living room laboratory into a thriving business with multiple portfolio companies since its creation in 2013. At this workshop, essential tips and key information were shared with attendees regarding how to start and maintain a prosperous business in this industry. This included mechanisms necessary to grow a…

News Release LaFayette, N.Y. —The State University of New York College of Environmental Science and Forestry (ESF) and Ichor Life Sciences (formerly Ichor Therapeutics) are partnering to train graduate students in researching drugs that could combat age-related illnesses. The educational component will occur at ESF, where students will focus on biochemistry, chemistry or bioprocess engineering. Their laboratory research will primarily occur at the facilities of Ichor Life Sciences in nearby LaFayette, New York. Ichor Life Sciences is a premium pre-clinical contract research organization offering services in discovery through pharmacology. The scientific study of human aging has exploded in recent years, driven by a growing understanding of age-related disease and associated molecular pathways. The use of drugs for targeted purposes, such as selectively destroying toxic senescent (aging) cells, has been identified as a method for increasing mammalian lifespan. This has led to a demand for qualified post-graduate-level scientists to support emerging…

News Release Philadelphis, Pa. and LaFayette, N.Y. — Today, Ship of Theseus, LLC, a bioengineering company that focuses on stem cell therapies for aging and age-associated disease, announces the initiation of a murine lifespan study to be conducted at Ichor Life Sciences, (formerly Ichor Therapeutics). This work will inform new targets for therapeutic intervention in aging. Ship of Theseus was founded to drastically extend the lifespans of our loved ones alive today. To meet our clinical deadlines, we invest intensively in validation of not only our specific technologies, but also our overarching paradigms, with robust and thorough studies. Our lifespan work with Ichor exemplifies this dedication and our mutual commitment to scientific rigor and agility make us ideal partners. – Jeremy Elser, Ph.D, CEO Ship of Theseus LLC Supplementing age-diminished bone marrow is known to extend lifespan in rodents. Translation to humans, however, has been precluded by immune rejection of…